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Abstract
Background: Patients	with	an	atrial	septal	defect	(ASD)	are	at	increased	risk	of	de‐
veloping	atrial	fibrillation	(AF).	Currently	percutaneous	ASD	closure	is	the	preferred	
therapeutic	strategy	and	although	pulmonary	vein	 isolation	(PVI)	for	AF	is	feasible	
after	ASD	closure,	the	transseptal	puncture	can	be	technically	challenging	and	prob‐
ably	increases	the	perioperative	risk.	A	staged	approach,	with	PVI	several	months	be‐
fore	ASD	closure,	has	been	recommended	for	patients	already	scheduled	for	closure,	
but	no	data	are	available	on	combined	procedures.
Purpose: This	pilot	study	evaluates	the	feasibility	of	a	combined	procedure	of	PVI	
and	ASD	closure	in	patients	with	a	hemodynamic	important	ASD	and	documented	
AF.
Methods: In	one	procedure,	PVI	was	performed	prior	to	placement	of	the	ASD	clo‐
sure	device.	Transseptal	access	for	PVI	was	obtained	via	wire	passage	through	the	
ASD	in	all	patients.	Patients	were	followed	with	5‐day‐holter	monitoring	at	3,	6,	and	
12	months.	Recurrence	of	AF	was	defined	as	a	documented,	symptomatic	episode	
of	AF.
Results: The	 study	 population	 consisted	 of	 five	 patients	 (four	 females,	mean	 age:	
58	(±3)	years).	Acute	PVI	was	achieved	in	all	patients.	Only	one	patient	had	a	small	
residual	ASD	after	closure.	Besides	a	small	groin	hematoma	in	two	patients,	no	com‐
plications	occurred.	After	12‐month	follow‐up,	three	patients	were	free	of	AF	recur‐
rence	(60%).
Conclusion: This	study	shows	that	a	combined	PVI	with	ASD	closure	is	feasible	with	
an	acceptable	success	rate	of	AF	free	survival.	These	preliminary	results	in	a	small	
patient	group	warrants	a	larger	trial.
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1  | INTRODUC TION
Evolving	treatment	options	in	patients	with	congenital	heart	disease	
(CHD)	resulted	in	an	improved	survival	and	a	rapidly	expanding	pa‐
tient	population	of	grown‐ups	with	CHD.	Atrial	septal	defect	(ASD)	
is	one	of	the	most	common	CHD	with	a	reported	birth	prevalence	
of	1–2	per	1000	live	births.1‐3	As	these	patients	age,	atrial	tachyar‐
rhythmias	are	common	complications,	mainly	atrial	fibrillation	(AF).4‐
6	The	prevalence	of	AF	 is	high	 in	ASD	patients	 (reported	between	
20%	and	45%),	with	the	first	episode	of	new‐onset	AF	at	a	younger	
age	as	compared	 to	 the	general	population.4,7‐12	Both	surgical	and	
percutaneous	closure	of	an	ASD	have	been	proven	as	an	effective	
treatment	of	a	significant	ASD	with	different	procedural	complica‐
tion	risks	and	rates	of	 residual	shunting.13	Closure	of	 the	ASD	has	
been	 associated	with	 a	higher	 risk	of	 developing	AF	as	well	 as	 an	
effective	treatment	of	AF,	but	evidence	is	inconsistent.9,11,14	In	the	
general	 population,	 various	 treatment	 options	 for	 AF	 have	 exten‐
sively	been	studied,	of	which	pulmonary	vein	isolation	(PVI)	has	been	
accepted	as	a	safe	and	effective	procedure.15,16	Less	is	known	about	
the	 preferred	 treatment	 strategy	 for	 AF	 in	 patients	with	 an	ASD,	
especially	 PVI,	 timing	 of	 PVI,	 for	 example	 before,	 after,	 or	 during	
ASD	closure.	Although	several	 studies	have	shown	 that	a	PVI	can	
be	safely	performed	in	patients	after	ASD	closure,	transseptal	punc‐
ture	can	be	troublesome	and	challenging	in	the	presence	of	a	closure	
device	 or	 patch.	 Successful	 transseptal	 punctures	 at	 native	 septal	
sites	or	directly	through	the	device	or	patch	have	been	described	in	
several	studies,	often	requiring	additional	tools	such	as	intracardiac	
echo	and	balloon	dilatation	through	an	Amplatzer	device.17‐21
Pulmonary	vein	isolation	in	patients	with	an	uncorrected	or	ASD	
is	feasible	with	reasonable	success	rates	ranging	between	56%	and	
75%	during	a	follow‐up	of	20	months	 in	18	and	4	patients,	respec‐
tively.	Left	atrial	access	can	be	obtained	through	the	defect	and	rarely 
requires	transseptal	puncture.22,23	In	case	if	transseptal	puncture	is	
required,	it	is	not	associated	with	additional	risks	compared	to	patients	
without	ASD.22,23	A	staged	procedure	of	PVI,	several	months	before	
percutaneous	closure,	has	been	advocated.22	One	of	the	drawbacks	
of	this	approach	is	that	these	patients	will	have	to	undergo	two	sepa‐
rate	procedures,	each	with	the	risk	of	procedural	complications.	Thus	
far	only	one	patient	with	concomitant	PVI	and	ASD	closure	has	been	
described	with	 transseptal	 access	 through	 the	ASD	and	 successful	
cryoballoon	ablation	prior	to	placement	of	a	septal	occluder	with	no	
residual	shunt	or	atrial	arrhythmia	at	one	year	follow‐up.24	Our	aim	
was	to	study	the	feasibility	and	safety	of	a	combined	approach	of	PVI	
and	ASD	closure	in	a	small	cohort	of	ASD	patients	with	symptomatic,	
documented	AF	and	the	one	year	success	rate.
2  | METHODS
This	pilot	study	was	approved	by	the	local	ethics	committee	in	the	
Radboud	 University	 Medical	 Center	 Nijmegen	 (METC	 number:	
2018‐4860).
2.1 | Inclusion
Patients	with	 an	 indication	 for	 ASD	 closure,	 defined	 according	 to	
current	clinical	guidelines;	significant	left‐to‐right	shunt	with	echo‐
cardiographic	signs	of	right	ventricle	volume	overload	25 and docu‐
mented,	symptomatic	AF.
2.2 | Periprocedural management
Prior	to	the	PVI,	a	computed	tomography	scan	was	obtained	to	ex‐
amine	the	three‐dimensional	anatomy	of	the	pulmonary	veins	(PVs).	
All	patients	used	oral	anticoagulation	therapy	prior	to	the	ablation	
procedure.	All	patients	were	on	a	novel	oral	anticoagulant	(NOAC),	
for	which	we	used	an	interrupted	regimen	consisting	of	a	NOAC‐free	
interval	of	12–24	hours	prior	to	the	procedure.
2.3 | Ablation procedure
All	 procedures	were	 performed	 under	 general	 anesthesia	 or	 con‐
scious	 sedation,	 with	 transesophageal	 echocardiography	 (TEE)	 to	
exclude	thrombi	in	the	left	atrium.
After	gaining	right	femoral	vein	access	and	sheath	placement,	
a	 steerable	 decapolar	 diagnostic	 catheter	was	 positioned	 in	 the	
coronary	 sinus.	 Access	 to	 the	 left	 atrium	 and	PVs	was	 obtained	
using	direct	wire	passage	through	the	septal	defect.	In	case	if	this	
could	 not	 be	 achieved,	 transseptal	 puncture	 (single	 or	 double)	
under	fluoroscopic	and	TEE	guidance	would	have	been	performed.	
During	 the	procedure,	 the	patient	heparin	was	administered	tar‐
geting	 an	 activated	 clotting	 time	 >300	 seconds.	 PVI	 using	 cryo	
energy	was	performed	using	 the	 second	generation	 cryoballoon	
(Medtronic,	Minneapolis,	MN,	USA)	 in	 combination	with	 the	12‐
French	 steerable	 sheath	 (Medtronic,	Minneapolis,	MN,	USA).	All	
the	 PVs	 were	 mapped	 with	 an	 inner	 lumen	 mapping	 catheter.	
Every	vein	was	treated	with	at	least	two	applications.	The	freeze	
cycles	 were	 180	 seconds.	 Balloon	 size	 of	 the	 cryoballoon	 was	
28	mm	in	all	cases.	Phrenic	nerve	palsy	was	monitored	during	ab‐
lation	 of	 the	 right‐sided	 PVs.	 PVI	 using	 radiofrequency	 (RF)	 en‐
ergy	was	performed,	guided	by	a	3‐D	electroanatomical	mapping	
system	(Ensite	Precision,	Abbott),	and	a	3.5	mm	irrigated	open‐tip	
catheter	was	used.	Ablative	therapy	was	performed	at	25–30	W,	
43°C	and	an	irrigation	rate	of	17	mL/min.	A	point‐by‐point	series	
of	interconnecting	focal	ablation	lesions	was	used	to	encircle	the	
left‐	 and	 right‐sided	 PV	 pairs.	 PVI	was	 confirmed	 using	 a	 steer‐
able	 multi‐electrode	 lasso	 catheter.	 No	 additional	 lines	 or	 focal	
lesions	were	made.	After	confirming	isolation	of	the	veins	an	over	
the	wire	change	to	an	Amplatzer	Torque	45°	delivery	system	was	
performed	 for	 the	 ASD	 closure.	 After	 TEE	 sizing,	 the	 appropri‐
ate	closure	device	was	delivered,	using	 fluoroscopy	guidance,	 to	
close	 the	defect.	Using	 contrast	 injection,	 residual	 defects	were	
ruled	out	and	after	confirmation	of	a	good	and	stable	position,	the	
implantation	 tool	was	 released	 and	 retracted.	 The	 day	 after	 the	
procedure,	a	transthoracic	echocardiogram	(TTE)	was	performed	
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to	exclude	pericardial	effusion	and	confirm	a	good	position	of	the	
closure	device.	The	patient	was	discharged	hereafter.
2.4 | Follow–up
Data	during	follow‐up	were	systematically	collected	and	included	
a	resting	ECG	and	physical	examination	during	regular	outpatient	
visits,	 as	well	 as	6‐day	holter	monitoring	at	3,	6,	and	12	months	
after	 ablation,	 but	 also	 symptom	driven	 consultation.	As	 recom‐
mended	 in	current	guidelines,	a	blanking	period	of	three	months	
after	 PVI	was	 applied.15	Oral	 anticoagulation	was	 continued	 for	
at	 least	 three	months	 after	 the	 procedure,	 after	which	 life‐long	
treatment	was	based	on	 the	CHA₂DS₂‐VASc	score.	Anti‐arrhyth‐
mic	drugs	were	stopped	or	continued	at	the	discretion	of	the	treat‐
ing	physician.
Recurrence	of	all	documented	AF	episodes,	all	procedure	related	
complications,	 procedure	 time,	 and	duration	of	hospital	 admission	
were	collected.
3  | RESULTS
Between	 September	 2016	 and	 August	 2017,	 five	 patients	 (four	
female,	 mean	 age	 58	 ±	 3	 years)	 were	 eligible	 for	 the	 combined	
procedure	of	PVI	and	ASD	closure;	baseline	and	procedural	char‐
acteristics	are	listed	in	Table	1.	All	patients	had	symptomatic	par‐
oxysmal	AF	with	 a	median	 time	 from	onset	 of	 symptoms	 to	 the	
procedure	of	26	months,	ranging	from	2	to	54	months.	The	max‐
imal	 CHA₂DS₂‐VASc	 score	was	 2	 and	 all	 patients	 used	 a	NOAC.	
Transseptal	access	for	PVI	was	obtained	via	wire	passage	through	
TA B L E  1  Clinical‐,	procedural‐	and	follow‐up	data
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age	(years) 58 49 59 66 58
Sex F F F F M
Comorbidity M.	Graves None Hypertension Hypercholesteromia Hypertension
BMI 25 24 24 29 26
ASD	size	(mm) 16 15 19 18 4	and	1
RVEDD	(inlet,mm) 47 43 40 43 52
Left	ventricle	systolic	function Normal Normal Normal Normal Normal
LVEDD	(mm) 46 43 38 35 50
Valve	disease No No No No No
left	atrial	size	(m1/m2) 29 43 32 25 48
duration	of	AF	(months)a  26 2 42 54 25
CHADSVASC	score 2 1 2 2 1
Anticoagulation Apixaban	bid Edoxaban	od Dabigatran	bid Apixaban	bid Apixaban	bid
Antiarrythmic	drug propranolol metoprolol nebivolol sotalol flecainide
PVI	technique Cryoballoon Cryoballoon Cryoballoon Cryoballoon RF	point‐by‐point
Balloon	size	(mm) 28 28 28 28 n.a.
Acute	isolation	pulmonary	veins Yes Yes Yes Yes yes
ASD	closure	device Amplatzer Amplatzer Amplatzer Amplatzer Gore	Cardioform	
Septal	Occluder
Size	closure	device	(mm) 28 18 24 20 30
Total	procedure	time	(min) 153 183 236 153 218
Fluoroscopy	time	(min) 24 Unknown 23 24 27
Hospital	admission	(days) 1 1 1 1 2
Complication Groin	hematoma No No Groin	hematoma No
AF	recurrence	at	3months No Yes No No No
AF	recurrence	at	6	months No Yes No No No
AF	recurrence	at	12	months No No No No Yes
Abbreviations:	LVEDD,	left	ventricle	end	diastolic	dimension;	PVI,	pulmonary	vein	isolation;	RVEDD,	right	ventricle	end	diastolic	dimension.
aDuration	defined	as	time	in	months	of	diagnosed	atrial	fibrillation	before	the	procedure.	
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the	ASD	in	all	patients	and	no	additional	transseptal	puncture	was	
needed.
Pulmonary	vein	isolation	was	achieved	in	all	patients	using	cryo‐
thermal	 (N	=	4)	or	RF	 (N	=	1)	energy.	Either	an	Amplatzer	closure	
device	 (N	=	4)	 or	 a	Gore	Cardioform	Septal	Occluder	 (N	=	1)	was	
implanted.	Median	procedure	and	fluoroscopy	time	were	183	(153–
236)	and	24	(23–27)	minutes,	respectively.	Figures	1	and	2	show	the	
fluoroscopy	and	TEE	images	of	one	of	the	procedures.
Immediately	after	closure,	TEE	showed	no	residual	ASD.	TTE	
performed	on	 the	 first	postprocedural	day	 confirmed	 stable	po‐
sition	 of	 the	 closure	 device	 and	 absence	 of	 pericardial	 effusion	
in	 all	 patients.	 Four	 patients	 were	 discharged	 on	 the	 first	 post‐
procedural	 day	 and	one	on	 the	 second.	 Every	patient	 continued	
to	use	oral	anticoagulants.	At	the	end	of	the	12‐month	follow‐up	
period,	three	patients	were	free	from	AF	recurrence.	One	patient	
had	 a	documented	 recurrence	of	AF	 at	 the	 three	 and	 six	month	
follow‐up	period.	Both	episodes	converted	spontaneously	to	sinus	
rhythm	and	additional	therapy	was	not	given.	Another	patient	had	
a	recurrence	of	AF	at	12‐month	follow‐up,	which	was	treated	with	
an	electrical	cardioversion.
3.1 | Complications
Besides	two	small	groin	hematoma	at	the	vascular	access	sites,	con‐
trolled	by	means	of	manual	 compression,	no	major	periprocedural	
complications	occurred.
4  | DISCUSSION
This	pilot	study	shows	that	a	combined	procedure	of	PVI	and	ASD	
closure	 in	 symptomatic	 AF	 patients	 and	 an	 indication	 for	 ASD	
closure	 is	 feasible	 and	 safe.	During	 the	 12‐month	 follow‐up	 pe‐
riod	 three	 of	 five	 patients	were	 free	 from	AF	 recurrence	 (60%).	
Interestingly,	both	patients	with	AF	recurrences	had	an	enlarged	
left	 atrium,	 known	 as	 a	 predictor	 of	 AF	 in	 general,	 and	 of	 PVI	
failure.26,27
Our	recurrence	rate	 is	comparable	to	the	rate	described	 in	pa‐
tients	 undergoing	PVI	with	 an	 uncorrected	ASD	 (44%).23	 Another	
study	 showed	 a	 comparable	 recurrence	 rate	 after	 PVI	 in	 patients	
with	a	previously	closed	ASD	(44%).20
F I G U R E  1  X‐ray	images	of	a	procedure.	Direct	wire	passage	through	the	defect	(A),	isolation	of	the	left	inferior	pulmonary	vein,	in	this	
case	with	CRYOballoon	(B)	and	measuring	and	placing	the	ASD	closure	device	(C	and	D)
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Lakkireddy	et	al	compared	outcomes	of	PVI	during	a	mean	fol‐
low‐up	of	15	months	between	patients	with	a	corrected	ASD	(51%	
percutaneous	closure	device	and	49%	surgical	repaired	ASD)	and	a	
matched	AF	control	group	and	found	no	significant	 in	recurrence	
rate	recurrence	rate	(18%	vs	24%,	P	=	0.6)	18	Our	recurrence	rates	
are	 similar	 to	 those	 reported	 for	 PVI	 in	 the	 general	 population,	
which	ranged	between	45%	and	89%.15	Also,	complications	did	not	
occur.
The	median	procedure	time	of	183	minutes	in	the	present	study	
seems	reasonable,	particularly	when	taking	into	account	that	this	is	
a	 combined	 procedure.	Our	 procedure	 time	 is	 only	 slightly	 longer	
than	the	mean	PVI	procedure	time	of	124	(cryoballoon)	and	141	min‐
utes	 (RF)	 in	the	FIRE	and	 ICE	study	and	the	162	 (cryoballoon)	and	
166	minutes	 (RF)	 in	 a	 recent	meta‐analysis	 on	 ablative	 therapy	 in	
PAF.28,29
The	consideration	to	perform	PVI	several	months	before	closure	
seems	reasonable	but	has	a	clear	downside	of	performing	two	pro‐
cedures	and	subsequent	exposure	to	twice	the	procedural	complica‐
tion	risks.	The	disadvantage	of	performing	a	PVI	and	ASD	closure	in	
one	single	procedure	is	that,	in	case	of	an	AF	recurrence,	a	redo	PVI	
may	 be	more	 challenging.	 Nevertheless,	 previous	 studies	 showed	
the	feasibility	of	transseptal	access,	although	requiring	the	need	of	
extra	image	modalities	or	other	tools.	These	studies	even	reported	
no	residual	defects,	independently	of	the	transseptal	access	sites	in‐
cluding	the	native	septum	or	the	closure	device	itself.17‐21
Taking	a	recurrence	rates	of	40%	after	PVI	into	account,	every	4	
out	of	10	patients	will	be	a	potential	candidate	for	a	redo	PVI.	The	
actual	 decision	 on	 performing	 the	 redo	procedure	will	 depend	on	
severity	of	symptoms	and	will	be	a	joint	decision	of	the	patient	and	
physician.	Nevertheless,	 if	 all	 patients	with	AF	 recurrences	would	
opt	for	a	redo	procedure,	four	patients	will	be	subjected	to	the	com‐
plication	risks	of	a	redo	procedures.
However,	 in	 the	 stepwise	 approach,	 every	 patient	will	 at	 least	
have	two	procedures.	It	might	be	questioned	whether	a	redo	PVI	in	
these	patients	should	be	performed	before	the	closure	procedure	or	
concomitant.	With	a	presumed	recurrence	rate	of	40%	and	all	pa‐
tients	with	AF	recurrences	undergoing	a	redo	procedure,	at	least	6	
out	of	10	patients	will	have	had	two	procedures	and	four	patients	
will	 even	 have	 undergone	 three	 procedures,	 when	 redo	 PVI	 and	
ASD	closure	done	separately.	Another	 issue	 to	be	 resolved	 in	 this	
approach	is	the	advised	waiting	times	between	procedures.
Although	the	available	data	are	positive	on	feasibility	of	perform‐
ing	PVI	in	patients	with	a	closure	device,	we	do	recognize	that	a	redo	
PVI	does	logically	introduce	a	slightly	higher	complication	risk.	This	
F I G U R E  2  TEE	images	of	an	ASD	closure	procedure.	The	septal	defect	(arrow	in	A),	with	clear	left‐to‐right	shunting	(B).	Measuring	the	
defect	(C)	and	the	closure	device	covering	the	defect	(D)
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is,	to	our	opinion,	insufficient	reason	to	expose	all	patients	to	at	least	
two	procedures	and	thereby	doubling	the	complication	risk	in	all	pa‐
tients.	Moreover,	our	limited	data	show	AF	recurrences	in	patients	
with	a	dilated	left	atrium	in	which	it	could	even	be	reasonable	to	con‐
sider	a	surgical	(eg,	epicardial	or	hybrid)	approach	in	case	of	a	redo	
procedure.	This	will	overcome	the	additional	challenge	of	puncturing	
through	or	passed	a	closure	device	and	its	inherent	additional	com‐
plication,	 such	as	device	dislodgement	and	septal	 laceration.	With	
limited	experience	and	possibly	a	publication	bias,	 this	might	even	
be	the	preferred	option	in	these	patients.	On	the	contrary,	left	atrial	
dilatation	is	probably	a	marker	of	disease	progression	and	it	would	
be	 interesting	to	be	able	to	treat	patients	earlier,	possibly	through	
screening	tools,	yet	to	be	developed.
In	 conclusion,	 the	preferred	 strategy	 for	 symptomatic	patients	
with	AF	accepted	for	ASD	closure	could	be	a	concomitant	procedure	
of	a	PVI	 followed	by	an	ASD	closure	with	a	 low	complication	risk.	
However,	larger	studies	are	needed	to	provide	further	evidence	that	
this	is	indeed	the	best	strategy	and	better	define	patient	character‐
istics	and	risk	factors	associated	with	outcome.
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